腘动脉及膝下动脉腔内治疗术后双联与单联抗血小板治疗的短期结局:来自荷兰慢性肢体威胁性缺血注册研究(THRILLER)的数据
该研究基于荷兰THRILLER多中心前瞻性注册数据回顾性分析,比较腘动脉及膝下动脉腔内治疗术后3个月双联抗血小板治疗(DAPT)与单联抗血小板治疗(SAPT)的疗效与安全性。共纳入460例患者,其中322例(70%)接受DAPT,138例(30%)接受SAPT。两组主要疗效复合终点及次要疗效终点均无显著差异,每组各观察到1例大出血。作者认为3个月DAPT不优于SAPT,需设计良好的随机试验进一步验证。
要点
- 腘动脉及膝下动脉腔内治疗术后3个月DAPT与SAPT的主要疗效复合终点无显著差异。
- SAPT组主要疗效复合终点事件21例(15.2%),DAPT组52例(16.1%)。
- 两组各观察到1例大出血,主要安全性终点无显著差异。
核心结论
- 研究结果提示,3个月DAPT不优于SAPT。
- 作者认为需要设计良好的随机试验来评估慢性肢体威胁性缺血患者接受腘动脉及膝下动脉腔内治疗后DAPT的疗效与安全性。
研究设计与样本
- 多中心注册研究的回顾性分析,数据来自荷兰慢性肢体威胁性缺血注册研究(THRILLER)前瞻性收集的2021年1月至2023年10月入组患者。
- 共纳入460例接受DAPT或SAPT抗血小板治疗的患者,其中322例(70%)接受DAPT,138例(30%)接受SAPT。
- 主要疗效终点为3个月主要不良心血管事件(MACE,即心肌梗死、脑血管事件、心血管死亡)、主要不良肢体事件(MALE,即大截肢、再干预)与非心血管死亡的复合终点。
- 次要疗效终点为3个月MACE、MALE及全因死亡率;主要安全性终点为根据「心肌梗死溶栓」(TIMI)分类定义的大出血。
- 采用描述性统计与Cox比例风险模型进行分析。
主要发现
- 共观察到73例(15.9%)主要疗效复合终点事件,其中SAPT组21例(15.2%),DAPT组52例(16.1%)。
- SAPT与DAPT在主要疗效复合终点及任何次要疗效终点方面均无显著差异。
- 两组各观察到1例大出血。
临床怎么用
- 作者认为,在考虑使用3个月DAPT时,SAPT似乎是足够的替代选择。
- 作者建议进一步研究验证这些结果,并关注腔内治疗后延长DAPT补充治疗的疗效与安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a lack of consensus regarding the optimal antithrombotic therapy (ATT) after popliteal and infrapopliteal (PIP) endovascular therapy (EVT). Currently, dual antiplatelet therapy (DAPT) for 3 months and single antiplatelet therapy (SAPT) are the most prescribed regimens in the Netherlands. Thus far, no randomized comparison has been performed on the optimal ATT approach. Therefore, this study compared the efficacy and safety of 3-month DAPT with SAPT following PIP EVT. DESIGN: Retrospective analysis of prospectively collected data from a multicenter registry. METHODS: The Dutch chronic lower limb-threatening ischemia registry (THRILLER) collected prospective data on patients enrolled between January 2021 and October 2023. As for ATT, only patients prescribed antiplatelet therapy (APT), were included in this analysis. The primary efficacy outcome was a composite of 3-month major adverse cardiovascular events (MACEs, ie, myocardial infarction, cerebrovascular event, cardiovascular death), major adverse limb events (MALEs, ie, major amputation, reintervention), and non-cardiovascular death. Secondary efficacy outcomes were 3-month MACE, MALE, and all-cause mortality. The primary safety outcome was major bleeding according to the 'Thrombolysis In Myocardial Infarction' (TIMI) classification. Descriptive statistics and Cox proportional hazard models were applied. RESULTS: In total, 460 of 840 THRILLER patients used DAPT or SAPT as ATT and were therefore included in the analysis. Of these, 322 (70%) received DAPT and 138 (30%) received SAPT. In total, 73 (15.9%) primary efficacy outcomes were observed of which 21 (15.2%) events in the SAPT group and 52 (16.1%) events in the DAPT group. No significant differences were observed between SAPT and DAPT for the primary efficacy outcomes or any of the secondary efficacy outcomes. In both groups, one case of major bleeding was observed. CONCLUSION: The findings suggest that 3 months of DAPT is not superior to SAPT. A well-powered randomized trial is warranted to assess the efficacy and safety of post-procedural DAPT in chronic limb-threatening ischemia (CLTI) patients undergoing PIP EVT.Clinical ImpactThis manuscript reports on the efficacy and safety outcomes of 3 months of DAPT versus SAPT, which are commonly chosen therapies following popliteal and infrapopliteal endovascular therapy. No significant difference was found between the two groups regarding major adverse cardiovascular events, all-cause death, major amputation, or major bleeding. Therefore, 3 months of DAPT does not seem superior to SAPT. These results suggest that SAPT appears to be a sufficient alternative when considering 3 months of DAPT. Further research should verify these outcomes and focus on the efficacy and safety of prolonged DAPT suppletion after endovascular therapy.
引用
- Wegerif ECJ, Nugteren MJ, van Galen IF, et al. Short-Term Outcomes of Dual Versus Single Antiplatelet Therapy Following Popliteal and Infrapopliteal Endovascular Therapy: Data From Dutch Chronic Lower Limb-Threatening Ischemia Registry (THRILLER). J Endovasc Ther. 2025. PMID: 39840536. doi:10.1177/15266028241312356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。